PDF(Pubmed)
Abstract：
OBJECTIVE: L-carnitine (LC), a vital nutritional supplement, plays a crucial role in myocardial health and exhibits significant cardioprotective effects. LC, being the principal constituent of clinical-grade supplements, finds extensive application in the recovery and treatment of diverse cardiovascular and cerebrovascular disorders. However, controversies persist regarding the utilization of LC in nervous system diseases, with varying effects observed across numerous mental and neurological disorders. This article primarily aims to gather and analyze database information to comprehensively summarize the therapeutic potential of LC in patients suffering from nervous system diseases while providing valuable references for further research.
METHODS: A comprehensive search was conducted in PubMed, Web Of Science, Embase, Ovid Medline, Cochrane Library and Clinicaltrials.gov databases. The literature pertaining to the impact of LC supplementation on neurological or psychiatric disorders in patients was reviewed up until November 2023. No language or temporal restrictions were imposed on the search.
RESULTS: A total of 1479 articles were retrieved, and after the removal of duplicates through both automated and manual exclusion processes, 962 articles remained. Subsequently, a meticulous re-screening led to the identification of 60 relevant articles. Among these, there were 12 publications focusing on hepatic encephalopathy (HE), while neurodegenerative diseases (NDs) and peripheral nervous system diseases (PNSDs) were represented by 9 and 6 articles, respectively. Additionally, stroke was addressed in five publications, whereas Raynaud\'s syndrome (RS) and cognitive disorder (CD) each had three dedicated studies. Furthermore, migraine, depression, and amyotrophic lateral sclerosis (ALS) each accounted for two publications. Lastly, one article was found for other symptoms under investigation.
CONCLUSIONS: In summary, LC has demonstrated favorable therapeutic effects in the management of HE, Alzheimer\'s disease (AD), carpal tunnel syndrome (CTS), CD, migraine, neurofibromatosis (NF), PNSDs, RS, and stroke. However, its efficacy appears to be relatively limited in conditions such as ALS, ataxia, attention deficit hyperactivity disorder (ADHD), depression, chronic fatigue syndrome (CFS), Down syndrome (DS), and sciatica.
METHODS: A comprehensive search was conducted in PubMed, Web Of Science, Embase, Ovid Medline, Cochrane Library and Clinicaltrials.gov databases. The literature pertaining to the impact of LC supplementation on neurological or psychiatric disorders in patients was reviewed up until November 2023. No language or temporal restrictions were imposed on the search.
RESULTS: A total of 1479 articles were retrieved, and after the removal of duplicates through both automated and manual exclusion processes, 962 articles remained. Subsequently, a meticulous re-screening led to the identification of 60 relevant articles. Among these, there were 12 publications focusing on hepatic encephalopathy (HE), while neurodegenerative diseases (NDs) and peripheral nervous system diseases (PNSDs) were represented by 9 and 6 articles, respectively. Additionally, stroke was addressed in five publications, whereas Raynaud\'s syndrome (RS) and cognitive disorder (CD) each had three dedicated studies. Furthermore, migraine, depression, and amyotrophic lateral sclerosis (ALS) each accounted for two publications. Lastly, one article was found for other symptoms under investigation.
CONCLUSIONS: In summary, LC has demonstrated favorable therapeutic effects in the management of HE, Alzheimer\'s disease (AD), carpal tunnel syndrome (CTS), CD, migraine, neurofibromatosis (NF), PNSDs, RS, and stroke. However, its efficacy appears to be relatively limited in conditions such as ALS, ataxia, attention deficit hyperactivity disorder (ADHD), depression, chronic fatigue syndrome (CFS), Down syndrome (DS), and sciatica.
摘要：
目标：左旋肉碱（LC），一种重要的营养补充剂，在心肌健康中起着至关重要的作用，并表现出显著的心脏保护作用。LC,作为临床级补充剂的主要成分，在各种心脑血管疾病的康复和治疗中发现了广泛的应用。然而,关于LC在神经系统疾病中的应用仍存在争议，在许多精神和神经系统疾病中观察到不同的效果。本文旨在收集和分析数据库信息，以全面总结LC在神经系统疾病患者中的治疗潜力，同时为进一步研究提供有价值的参考。
方法：在PubMed中进行了全面搜索，网络科学,Embase,OvidMedline,Cochrane图书馆和Clinicaltrials.gov数据库。直到2023年11月，有关LC补充对患者神经或精神疾病的影响的文献进行了回顾。对搜索没有语言或时间限制。
结果：共检索到1479篇，在通过自动和手动排除过程删除重复项之后，仍然有962条。随后，经过细致的重新筛选，确定了60篇相关文章。其中,有12篇出版物关注肝性脑病（HE），而神经退行性疾病(NDs)和周围神经系统疾病(PNSDs)分别为9篇和6篇，分别。此外,中风在五份出版物中得到了解决，而雷诺综合征（RS）和认知障碍（CD）各有三项专门研究。此外，偏头痛,抑郁症,和肌萎缩侧索硬化症（ALS）各占两份出版物。最后,在调查中发现了一篇其他症状的文章。
结论：总之，LC在HE的管理中表现出良好的治疗效果，阿尔茨海默病（AD），腕管综合征（CTS），CD,偏头痛,神经纤维瘤病（NF），PNSDs,RS,和中风。然而,在ALS等情况下，其功效似乎相对有限，共济失调,注意缺陷多动障碍（ADHD），抑郁症,慢性疲劳综合征（CFS），唐氏综合症（DS），和坐骨神经痛.
方法：在PubMed中进行了全面搜索，网络科学,Embase,OvidMedline,Cochrane图书馆和Clinicaltrials.gov数据库。直到2023年11月，有关LC补充对患者神经或精神疾病的影响的文献进行了回顾。对搜索没有语言或时间限制。
结果：共检索到1479篇，在通过自动和手动排除过程删除重复项之后，仍然有962条。随后，经过细致的重新筛选，确定了60篇相关文章。其中,有12篇出版物关注肝性脑病（HE），而神经退行性疾病(NDs)和周围神经系统疾病(PNSDs)分别为9篇和6篇，分别。此外,中风在五份出版物中得到了解决，而雷诺综合征（RS）和认知障碍（CD）各有三项专门研究。此外，偏头痛,抑郁症,和肌萎缩侧索硬化症（ALS）各占两份出版物。最后,在调查中发现了一篇其他症状的文章。
结论：总之，LC在HE的管理中表现出良好的治疗效果，阿尔茨海默病（AD），腕管综合征（CTS），CD,偏头痛,神经纤维瘤病（NF），PNSDs,RS,和中风。然而,在ALS等情况下，其功效似乎相对有限，共济失调,注意缺陷多动障碍（ADHD），抑郁症,慢性疲劳综合征（CFS），唐氏综合症（DS），和坐骨神经痛.
